|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Receivables | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total operating lease right-of-use assets | ||||||||||||||||||||
| Financing lease right-of-use assets | ||||||||||||||||||||
| Excluding Related Party | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders’ Equity (Deficiency) | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Current portion of liabilities for legal matters | ||||||||||||||||||||
| Revolving credit facility | ||||||||||||||||||||
| Current portion of long-term debt, net | ||||||||||||||||||||
| Current portion of operating lease liabilities | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Current portion of operating lease liabilities - related party | ||||||||||||||||||||
| Current portion of financing lease liabilities | ||||||||||||||||||||
| Excluding Related Party | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Current portion of notes payable - related party | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term debt, net | ||||||||||||||||||||
| Note payable - related party | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Financing lease liabilities | ||||||||||||||||||||
| Excluding Related Party | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related party payables - long term | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Liabilities for legal matters - long term | ||||||||||||||||||||
| Total long-term liabilities | ||||||||||||||||||||
| Redeemable non-controlling interests | ||||||||||||||||||||
| Stockholders’ Equity (Deficiency) | ||||||||||||||||||||
| Preferred stock, $0.01 par value, 2,000 shares authorized at both June 30, 2026 and December 31, 2025; none issued at both June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Common stock | ||||||||||||||||||||
| Common Class A | ||||||||||||||||||||
| Common Class B | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Stockholders’ accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total Amneal Pharmaceuticals, Inc. stockholders’ equity (deficiency) | ||||||||||||||||||||
| Non-controlling interests | ||||||||||||||||||||
| Total stockholders’ equity (deficiency) | ||||||||||||||||||||
| Total liabilities and stockholders’ equity (deficiency) | ||||||||||||||||||||
| Preferred stock, shares issued (in shares) | ||||||||||||||||||||
Loading...
